Childhood Cancer Statistics, England, Annual report 2018.

Slides:



Advertisements
Similar presentations
TA OGUNLESI (FWACP)1 OVERVIEW OF CHILDHOOD CANCERS.
Advertisements

Section 7 Nomenclature and classification. All tumors (benign and malignant) have two basic components. Proliferating neoplastic cells that constitute.
Brain Tumors Lindsay A Wilson, pgy2 AM Report 1/27/2010.
Pediatric Neurosurgical Neuropathology
Challenges and Considerations in Linking Adult and Pediatric CNS Malignancies Henry S. Friedman, MD The Brain Tumor Center at Duke.
Childhood leukaemia in Great Britain: trends in incidence, survival and ‘cure’ Anjali Shah UK Association of Cancer Registries conference 30 September.
Brain tumor.
Perspectives on CNS Malignancies Susan M. Staugaitis, M.D., Ph.D. Cleveland Clinic Foundation.
© Cancer Research UK 2011 Registered charity in England and Wales ( ) and Scotland (SC041666) Incidence 2008 – UK April 2011.
© Cancer Research UK 2003 Registered charity number Leukaemia The statistics in this presentation are based on the Leukaemia CancerStats report.
© Cancer Research UK 2012 Registered charity in England and Wales ( ) and Scotland (SC041666) Incidence 2009 – UK June 2012.
Tumors of the CNS can be: Primary Secondary
Setting the scene Louise Soanes TCT Nurse Consultant for AYA The Royal Marsden NHS Foundation Trust.
TRANSFORMING THE CHILDHOOD CANCER SURVIVOR EXPERIENCE Additional Material.
Incidence of Childhood Cancer. What is cancer ? Uncontrolled growth of cells Are these cancer cells abnormal? No, but their behaviour is.
Pediatric Pathology. “Children are not merely little adults, and their diseases are not merely variants of adult diseases”
Cancer: A disease in which abnormal cells multiply out of control, spread into surrounding tissues and other body parts, and disrupt normal functioning.
Systemic Pathology. Neoplasia -Abnormal cell growth.
Information network on rare cancers INFORMATION NETWORK ON RARE CANCERS (RARECARENet) Kick-off meeting - Friday, July Gemma Gatta Fondazione IRCCS,
START PROGRAM: STATE-OF-THE-ART ONCOLOGY IN EUROPE RARECARENet kick-off Luxembourg – July 13, 2012 Chairperson: Dr. Lisa Licitra.
Tumors  Gliomas  Neuronal tumors  Poorly differentiated neoplasms  Other parenchymal tumors  Meningiomas  Paraneoplastic syndromes  Peripheral.
© Cancer Research UK 2005 Registered charity number Table One: Numbers and rates of new cases, non-Hodgkin lymphoma, UK, 2006 EnglandWalesScotlandN.IrelandUK.
Pathology of the age of development DISSCUSED PROBLEMS I. Subject of the pathology of the age of development II. Pediatric neoplasia (neoplasms of the.
Estimating the population-based incidence for sarcoma and GIST in three European regions G. Mastrangelo University of Padova.
INTRODUCTION TO PEDIATRIC ONCOLOGY Prof.Dr.Reha Cengizlier
Brain:Spinal cord tumors 10:1
Data quality of leukaemia experiences in the Netherlands
In humans, billions of cells die each day Cells die in two ways: 1.Necrosis 2.Apoptosis.
Currently, most children with cancer are cured in affluent countries.
CONGENITAL NEVI. Common Malignant Neoplasms of Infancy and ChildhoodCommon Malignant Neoplasms of Infancy and Childhood 0 to 4 Years5 to 9 Years10 to.
I’m not just a child. I’m a daughter. I’m a son. I’m also a friend, a parent, a wife, a husband…
* Cases diagnosed from 1992 to 1995 Childhood and adolescent cancer survival: A period analysis of data from the Canadian Cancer Registry Larry F. Ellison,
In describing a person’s cancer what would T2 mean? In describing a person’s cancer what does M1 mean? In describing a person’s cancer what does N0 mean?
Autism linked to increased oncogene mutations but decreased cancer rate Additional Supporting Information Figures A-C Tables A-D.
Incidence Childhood cancer is rare - around 1,600 new cases are diagnosed every year in the UK (in children aged 0 to 14 years). This means that around.
Brain tumor.
Lindsay A Wilson, pgy2 AM Report 1/27/2010
Chapter 11 Cancer in Children.
COLORECTAL CANCER: Global Trends & Implications for Uganda
PEDITRIC ONCOLOGY AN INTRODUCTION
Paediatric Oncology CWMH 2016
Paediatric Oncology in Tonga
Malignancies in patients less than 6 months at MAHAK hospital
The Five Most Common Cancers:
Neurological Neoplasm FOM, KFMC
Table 3. Age Distribution of Solid Malignant Tumours in Children
Soft Tissue Sarcoma (All Subtypes Combined): 2010
Haematological Cancers:
Common childhood cancers similar in boys and girls (Mar. 2013)
Childhood cancer registration in England: 2015 to 2016, National Cancer Registration and Analysis Service Charts from the report.
The Five Most Commonly Diagnosed Cancers in Females
ORBITAL TUMOURS 1. Vascular tumours 2. Lacrimal gland tumours
Soft Tissue Sarcoma (All Subtypes Combined):
Pediatric Neurosurgical Neuropathology
Supplementary Figures
The Five Most Common Cancers:
Childhood Cancer Polly Bennion.
The 5 Most Commonly Diagnosed Cancers in Males
5 Prevalence Ontario Cancer Statistics 2016 Chapter 5: Prevalence.
Brain, Other CNS and Intracranial Tumours by Morphology:
Most Common Causes of Cancer Death in Males
The 20 Most Common Cancers in 2012
The 5 Most Commonly Diagnosed Cancers in Males
Statistically Significant Cancers, Females, England,
Volume 164, Issue 5, Pages (February 2016)
Intro to Cancer.
Evaluation of the Association between Paternal Occupational Exposure and Children Cancers (Leukemia and Non-Hodgkin lymphoma) Atef Atefi.
The 10 Most Common Cancers: 2013
Haematological Cancers:
Fig. 3. Survival rates according to histologic diagnosis
Presentation transcript:

Appendix C: Childhood Cancer Statistics, England, Annual report 2018 Survival Charts

Childhood Cancer Statistics, England, Annual report 2018. Population-based 5-year survival of children with cancer in England diagnosed 2001 to 2015, by period of diagnosis, grouped according to ‘International Classification of Childhood Cancer, Third Edition’ (ICCC-3) The study closing date for follow-up was 31 December 2016. Observed survival was estimated actuarially by Kaplan-Meier analysis. For diagnostic categories with at least 100 registrations analysed, results are given for children diagnosed during each of the 3 5-year periods 2001-2005, 2006-2010 and 2011-2015. For those with fewer than 100 registrations, results are given for the single 15-year period 2001-2015. For more information on the data and methods used for the survival analysis, please refer to the main report. Childhood Cancer Statistics, England, Annual report 2018. Source: National Cancer Registration and Analysis Service, Public Health England, CAS accessed December 2017

Childhood Cancer Statistics, England, Annual report 2018. Source: National Cancer Registration and Analysis Service, Public Health England, CAS accessed December 2017

Childhood Cancer Statistics, England, Annual report 2018. Source: National Cancer Registration and Analysis Service, Public Health England, CAS accessed December 2017

Childhood Cancer Statistics, England, Annual report 2018. Figure 1: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, all cancers combined Childhood Cancer Statistics, England, Annual report 2018. Source: National Cancer Registration and Analysis Service, Public Health England, CAS accessed December 2017

Childhood Cancer Statistics, England, Annual report 2018. Figure 2: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, leukaemias, myeloproliferative diseases, and myelodysplastic diseases Childhood Cancer Statistics, England, Annual report 2018. Source: National Cancer Registration and Analysis Service, Public Health England, CAS accessed December 2017

Childhood Cancer Statistics, England, Annual report 2018. Figure 3: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, lymphoid leukaemias Childhood Cancer Statistics, England, Annual report 2018. Source: National Cancer Registration and Analysis Service, Public Health England, CAS accessed December 2017

Childhood Cancer Statistics, England, Annual report 2018. Figure 4: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, precursor cell leukaemias Childhood Cancer Statistics, England, Annual report 2018. Source: National Cancer Registration and Analysis Service, Public Health England, CAS accessed December 2017

Childhood Cancer Statistics, England, Annual report 2018. Figure 5: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, precursor cell leukaemias - aged <1 Childhood Cancer Statistics, England, Annual report 2018. Source: National Cancer Registration and Analysis Service, Public Health England, CAS accessed December 2017

Figure 6: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, precursor cell leukaemias - aged 1-14 Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 7: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, mature B-cell leukaemias Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 8: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, acute myeloid leukaemias Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 9: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, chronic myeloproliferative diseases Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 10: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, chronic myeloid leukaemia Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 11: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, other chronic myeloproliferative diseases Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 12: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, myelodysplastic syndrome and other myeloproliferative diseases Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 13: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, myelodysplastic syndrome Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 14: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, juvenile myelomonocytic leukaemia and chronic myelomonocytic leukaemia Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 15: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, unspecified and other specified leukaemias Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 16: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, lymphomas and reticuloendothelial neoplasms Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 17: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, Hodgkin lymphoma Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 18: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, Non-Hodgkin lymphomas (including Burkitt lymphoma) Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 19: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, CNS and miscellaneous intracranial and intraspinal neoplasms Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 20: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, ependymomas and choroid plexus tumour Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 21: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, ependymomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 22: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, choroid plexus carcinoma Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 23: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, choroid plexus papilloma Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 24: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, astrocytomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 25: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, medulloblastoma Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 26: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, embryonal CNS tumour NOS Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 27: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, atypical teratoid/rhabdoid tumour Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 28: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, oligodendrogliomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 29: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, mixed and unspecified gliomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 30: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, pituitary adenomas and carcinomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 31: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, tumours of the sellar region (craniopharyngiomas) Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 32: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, pineal parenchymal tumours Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 33: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, neuronal and mixed neuronal-glial tumours Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 34: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, meningiomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 35: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, neuroblastoma and other peripheral nervous cell tumours Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 36: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, neuroblastoma and ganglioneuroblastoma Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 37: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, neuroblastoma and ganglioneuroblastoma - aged <1 Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 38: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, neuroblastoma and ganglioneuroblastoma - aged 1-14 Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 39: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, retinoblastoma Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 40: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, retinoblastoma: bilateral Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 41: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, retinoblastoma: unilateral Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 42: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, renal tumours Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 43: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, nephroblastoma (Wilms Tumour) Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 44: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, rhabdoid renal tumour Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 45: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, kidney sarcomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 46: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, hepatic tumours Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 47: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, hepatoblastoma Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 48: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, hepatic carcinomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 49: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, malignant bone tumours Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 50: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, osteosarcomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 51: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, Ewing tumour and related sarcomas of bone Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 52: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, soft tissue and other extraosseous sarcomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 53: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, rhabdomyosarcomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 54: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, fibroblastic and myofibroblastic tumours Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 55: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, nerve sheath tumours Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 56: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, extraosseous Ewing sarcoma family tumours Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 57: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, extrarenal rhabdoid tumour Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 58: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, synovial sarcomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 59: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, hepatic sarcomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 60: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, germ cell tumours, trophoblastic tumours, and neoplasms of gonads Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 61: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, CNS germinoma Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 62: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, non-germinoma Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 63: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, malignant extracranial and extragonadal germ cell tumours Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 64: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, gonadal germ cell tumours: female Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 65: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, gonadal germ cell tumours: male Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 66: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, other malignant epithelial neoplasms and malignant melanomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 67: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, adrenocortical carcinomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 68: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, thyroid carcinomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 69: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, nasopharyngeal carcinomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 70: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, malignant melanomas Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015

Figure 71: Population-based survival of children aged 0–14 years with cancer in England diagnosed 2001 to 2015, other and unspecified malignant neoplasms Childhood Cancer Statistics, England, Annual report 2018 Cancer registrations 2001-2015